Results 81 to 90 of about 197,953 (330)
Allergy and Asthma Proceedings, 2021 BACKGROUND Novel subcutaneous (SC) prophylactic therapies are transforming the treatment landscape of hereditary angioedema(HAE). Although questions are being raised about their cost, little attention has been paid to the cost and quality of life (QoL ...
A. Castaldo +5 more
semanticscholar +1 more source
Phenothiazine Derivatives and Their Impact on the Apoptosis Processes: A Review
Journal of Applied Toxicology, EarlyView.ABSTRACT Phenothiazine derivatives have been used for decades as antipsychotic drugs in multiple mental health and physical conditions treatment (schizophrenia, mania in bipolar disorder, and psychosis). Epidemiological studies have shown that people with schizophrenia are less likely to suffer from cancer, which indicates the ability of antipsychotics
Michał Otręba +4 more
wiley +1 more source
Allergy, Asthma & Clinical Immunology, 2010 Background We published the Canadian 2003 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema (HAE; C1 inhibitor [C1-INH] deficiency) and updated this as Hereditary angioedema: a current state-of-the-art ...
Bowen Tom +59 more
doaj +1 more source
Bradykinin-Mediated Angioedema Induced by Commonly Used Cardiovascular Drugs
Drugs and Drug Candidates, 2023 ACE inhibitors, sartans, and sacubitril are among the most important drugs for the prevention of cardiovascular mortality and morbidity. At the same time, they are known to cause non-allergic bradykinin-mediated angioedema, a potentially fatal swelling ...
Janina Hahn +3 more
doaj +1 more source
Blood Clotting and the Pathogenesis of Types I and II Hereditary Angioedema
Clinical reviews in allergy and immunology, 2021 The plasma contact system is the initiator of the intrinsic pathway of coagulation and the main producer of the inflammatory peptide bradykinin.
S. de Maat +3 more
semanticscholar +1 more source
The Journal of Clinical Pharmacology, EarlyView.Abstract In Japan, the percentage of approved drugs with pediatric indications increased to 30% in 2010‐2015, but no further increase was observed through 2020. The Ministry of Health, Labor, and Welfare in Japan presented draft future directions to promote pediatric drug development, where the modeling and simulation (M&S) approach was introduced as a
Akinori Nakashima +5 more
wiley +1 more source
Clinics, 2018 Hereditary angioedema is an autosomal dominant disease characterized by recurrent angioedema attacks with the involvement of multiple organs. The disease is unknown to many health professionals and is therefore underdiagnosed.
Pedro Giavina-Bianchi +26 more
doaj +1 more source
Roles of Immune Cells in Hereditary Angioedema
Clinical reviews in allergy and immunology, 2021 Hereditary angioedema (HAE) is a rare genetic disease, characterized by recurrent and unexpected potentially life-threatening mucosal swelling. HAE may be further classified into HAE with C1‐inhibitor deficiency (C1‐INH‐HAE) and HAE with normal C1‐INH ...
A. L. Ferrara +11 more
semanticscholar +1 more source
Pediatric hereditary angioedema [PDF]
Pediatric Allergy and Immunology, 2013 AbstractHereditary angioedema (HAE) is a lifelong illness characterized by recurrent swelling of the skin, intestinal tract, and, ominously, the upper airway. It is caused by inadequate activity of the protein C1‐inhibitor, with dysfunction in the kallikrein/bradykinin pathway underlying the clinical symptoms.
openaire +4 more sources
The Journal of Clinical Pharmacology, EarlyView.Abstract Garadacimab is a novel, fully human, anti‐activated factor XII monoclonal antibody approved for long‐term prophylaxis of patients with hereditary angioedema. This open‐label, parallel‐group, Phase 1, single‐center, bridging study in healthy adults (18–55 years of age) characterized the pharmacokinetics and safety of a single 200 mg ...
Fiona Glassman +9 more
wiley +1 more source